Nanosized extracellular vesicles derived from bacteria contain diverse cargo and transfer intercellular bioactive molecules to cells.Due to their favorable intercellular interactions,cell membrane-derived bacterial ex...Nanosized extracellular vesicles derived from bacteria contain diverse cargo and transfer intercellular bioactive molecules to cells.Due to their favorable intercellular interactions,cell membrane-derived bacterial extracellular vesicles(BEVs)have great potential to become novel drug delivery platforms.In this review,we summarize the biogenesis mechanism and compositions of various BEVs.In addition,an overview of effective isolation and purification techniques of BEVs is provided.In particular,we focus on the application of BEVs as bioactive nanocarriers for drug delivery.Finally,we summarize the advances and challenges of BEVs after providing a comprehensive discussion in each section.We believe that a deeper understanding of BEVs will open new avenues for their exploitation in drug delivery applications.展开更多
Cancer therapy is undergoing a paradigm shift toward immunotherapy focusing on various approaches to activate the host immune system.As research to identify appropriate immune cells and activate anti-tumor immunity co...Cancer therapy is undergoing a paradigm shift toward immunotherapy focusing on various approaches to activate the host immune system.As research to identify appropriate immune cells and activate anti-tumor immunity continues to expand,scientists are looking at microbial sources given their inherent ability to elicit an immune response.Bacterial extracellular vesicles(BEVs)are actively studied to control systemic humoral and cellular immune responses instead of using whole microorganisms or other types of extracellular vesicles(EVs).BEVs also provide the opportunity as versatile drug delivery carriers.Unlike mammalian EVs,BEVs have already made it to the clinic with the meningococcal vaccine(Bexsero®).However,there are still many unanswered questions in the use of BEVs,especially for chronic systemically administered immunotherapies.In this review,we address the opportunities and challenges in the use of BEVs for cancer immunotherapy and provide an outlook towards development of BEV products that can ultimately translate to the clinic.展开更多
基金supported by the National Key R&D Program of China(2018YFC2001500)National Natural Science Foundation of China(NSFC)Key Research Program in Aging(91749204)National Natural Science Foundation of China(82172098,81771491,81972254).
文摘Nanosized extracellular vesicles derived from bacteria contain diverse cargo and transfer intercellular bioactive molecules to cells.Due to their favorable intercellular interactions,cell membrane-derived bacterial extracellular vesicles(BEVs)have great potential to become novel drug delivery platforms.In this review,we summarize the biogenesis mechanism and compositions of various BEVs.In addition,an overview of effective isolation and purification techniques of BEVs is provided.In particular,we focus on the application of BEVs as bioactive nanocarriers for drug delivery.Finally,we summarize the advances and challenges of BEVs after providing a comprehensive discussion in each section.We believe that a deeper understanding of BEVs will open new avenues for their exploitation in drug delivery applications.
文摘Cancer therapy is undergoing a paradigm shift toward immunotherapy focusing on various approaches to activate the host immune system.As research to identify appropriate immune cells and activate anti-tumor immunity continues to expand,scientists are looking at microbial sources given their inherent ability to elicit an immune response.Bacterial extracellular vesicles(BEVs)are actively studied to control systemic humoral and cellular immune responses instead of using whole microorganisms or other types of extracellular vesicles(EVs).BEVs also provide the opportunity as versatile drug delivery carriers.Unlike mammalian EVs,BEVs have already made it to the clinic with the meningococcal vaccine(Bexsero®).However,there are still many unanswered questions in the use of BEVs,especially for chronic systemically administered immunotherapies.In this review,we address the opportunities and challenges in the use of BEVs for cancer immunotherapy and provide an outlook towards development of BEV products that can ultimately translate to the clinic.
